石四药集团：利奈唑胺干混悬剂获药监局批件

和讯网04-23

【石四药集团获得利奈唑胺干混悬剂生产批件】石四药集团今日公告，已成功获得中国国家药品监督管理局颁发的利奈唑胺干混悬剂药品生产注册批件。该药品属于化学药品第4类，标志着公司通过了一致性评价。公告中指出，利奈唑胺干混悬剂为口服混悬剂型，石四药集团成为国内首家获此殊荣的企业。此前，该集团已获得利奈唑胺原料药及注射剂的生产批件。利奈唑胺干混悬剂适用于新生儿、儿童及成年患者，主要用于治疗由特定微生物敏感株...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2429615863?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-23 13:20","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2429615863","market":"hk","top_or_hot":-1,"title":"石四药集团：利奈唑胺干混悬剂获药监局批件","media":"和讯网","content":"<div>\n<p>【石四药集团获得利奈唑胺干混悬剂生产批件】 石四药集团今日公告，已成功获得中国国家药品监督管理局颁发的利奈唑胺干混悬剂药品生产注册批件。该药品属于化学药品第4类，标志着公司通过了一致性评价。公告中指出，利奈唑胺干混悬剂为口服混悬剂型，石四药集团成为国内首家获此殊荣的企业。此前，该集团已获得利奈唑胺原料药及注射剂的生产批件。利奈唑胺干混悬剂适用于新生儿、儿童及成年患者，主要用于治疗由特定微生物敏感株...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313431187a4681b&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石四药集团：利奈唑胺干混悬剂获药监局批件</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石四药集团：利奈唑胺干混悬剂获药监局批件\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-23 13:20 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313431187a4681b&s=b><strong>和讯网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【石四药集团获得利奈唑胺干混悬剂生产批件】 石四药集团今日公告，已成功获得中国国家药品监督管理局颁发的利奈唑胺干混悬剂药品生产注册批件。该药品属于化学药品第4类，标志着公司通过了一致性评价。公告中指出，利奈唑胺干混悬剂为口服混悬剂型，石四药集团成为国内首家获此殊荣的企业。此前，该集团已获得利奈唑胺原料药及注射剂的生产批件。利奈唑胺干混悬剂适用于新生儿、儿童及成年患者，主要用于治疗由特定微生物敏感株...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313431187a4681b&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02005","symbol_name":"石四药集团","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313431187a4681b&s=b","article_id":"2429615863","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313431187a4681b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2429615863","pubTimestamp":1713849615,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"【石四药集团获得利奈唑胺干混悬剂生产批件】 石四药集团今日公告，已成功获得中国国家药品监督管理局颁发的利奈唑胺干混悬剂药品生产注册批件。该药品属于化学药品第4类，标志着公司通过了一致性评价。公告中指出，利奈唑胺干混悬剂为口服混悬剂型，石四药集团成为国内首家获此殊荣的企业。此前，该集团已获得利奈唑胺原料药及注射剂的生产批件。利奈唑胺干混悬剂适用于新生儿、儿童及成年患者，主要用于治疗由特定微生物敏感株引起的院内获得性肺炎、社区获得性肺炎、皮肤和皮肤软组织感染，以及万古霉素耐药的屎肠球菌感染。此次批件的获得，预计将为该集团带来新的市场机遇和盈利增长点。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02005":"石四药集团","BK1191":"制药"},"translate_title":"Shisi Pharmaceutical Group: Linezolid dry suspension was approved by the Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02005":1},"content_text":"【石四药集团获得利奈唑胺干混悬剂生产批件】 石四药集团今日公告，已成功获得中国国家药品监督管理局颁发的利奈唑胺干混悬剂药品生产注册批件。该药品属于化学药品第4类，标志着公司通过了一致性评价。公告中指出，利奈唑胺干混悬剂为口服混悬剂型，石四药集团成为国内首家获此殊荣的企业。此前，该集团已获得利奈唑胺原料药及注射剂的生产批件。利奈唑胺干混悬剂适用于新生儿、儿童及成年患者，主要用于治疗由特定微生物敏感株引起的院内获得性肺炎、社区获得性肺炎、皮肤和皮肤软组织感染，以及万古霉素耐药的屎肠球菌感染。此次批件的获得，预计将为该集团带来新的市场机遇和盈利增长点。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2429615863"}